Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Thrombocytopenia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1Anemia 1

Interventions

Epoetin Alfa 55Darbepoetin alfa 39epoetin beta 14ferric carboxymaltose 11Lenalidomide 5Cyclophosphamide 5luspatercept 4fludarabine phosphate 4fludarabine 4Erythropoietin 4Cyclosporine 4Cisplatin 4Busulfan 4Blood Transfusion 4Biopsy 4ACE-011 4peginesatide 3iron isomaltoside 1000 3hematide 3ferrous sulfate 3ferric gluconate 3Radiotherapy 3Iron-Dextran Complex 3Filgrastim 3Ferric Oxide, Saccharated 3Erythrocyte Transfusion 3Antilymphocyte Serum 3thymoglobulin 2telapristone acetate 2ruxolitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × alvocidib × Classical hematology × Clear all
NCT00735930 2015-04-02

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
39 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡